ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
67,862.71
0.41%
S&P 500
5,266.95
-0.74%
Dow Jones
38,441.54
0.00%
US Dollar vs Yen
156.7295
-0.56%
Brent Oil
82.955
-0.50%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Aridis Pharmaceuticals Inc (ARDS)

  7. Aridis Pharmaceuticals Inc (ARDS) ニュース

ARDS

Aridis Pharmaceuticals (ARDS)

Aridis Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:ARDS
日付受信時刻ニュースソース見出しコード企業名
2024/02/1410 : 02Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
2024/01/1620 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/12/1606 : 15GlobeNewswire Inc.Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/11/0406 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/11/0405 : 15GlobeNewswire Inc.Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/11/0319 : 15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/09/1410 : 47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/09/0805 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/08/2605 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/08/0505 : 05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/08/0505 : 05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/08/0405 : 15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/08/0221 : 17GlobeNewswire Inc.Aridis Pharmaceuticals Announces $2 Million OfferingNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/08/0213 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/07/2119 : 49Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/07/2106 : 18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/07/1805 : 05GlobeNewswire Inc.Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/07/1804 : 01Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/07/1720 : 36Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/07/1221 : 00GlobeNewswire Inc.Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) DesignationNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/06/2319 : 01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/06/2021 : 00GlobeNewswire Inc.Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/06/1606 : 16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/06/1606 : 14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/06/1606 : 13Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/06/1606 : 10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/06/0919 : 13Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/06/0919 : 01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARDSAridis Pharmaceuticals Inc
2023/06/0905 : 05GlobeNewswire Inc.Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business UpdateNASDAQ:ARDSAridis Pharmaceuticals Inc
2023/05/3121 : 00GlobeNewswire Inc.Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study DesignNASDAQ:ARDSAridis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ARDS

最近閲覧した銘柄

BIT
P1FSD6
BNP Paribas Issuance
BIT
F34696
Vontobel Financial Produ...
BIT
F34839
Vontobel Financial Produ...
COIN
SMARTBETH
BIT
F39550
Vontobel Financial Produ...
BIT
P90503
Bnp Paribas Issuance
BIT
F39639
Vontobel Financial Produ...
KOSPI
005110
Hanchang
BIT
F39332
Vontobel Financial Produ...
BIT
P1TAJ2
BNP Paribas Issuance
BIT
P1PVD9
BNP Paribas Issuance
BIT
P1LBR0
BNP Paribas Issuance
BIT
P1SS42
BNP Paribas Issuance
BIT
P1NZ71
BNP Paribas Issuance
USOTC
AMRRY
American Rare Earths (QX)
BIT
P1KTK9
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有